Anesderm

Quick links to important sections

Anesderm

Method of action: Anesthetic, Local Anesthetic

Treatment option: Anesthesia, Surgery

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anesderm

Quick Facts

Property Description
Active ingredients Lidocaine Hydrochloride, Prilocaine
Form Topical Cream (Eutectic Mixture)
Pharmacological class Amide-type Local Anesthetic Agents
Common use Dermal Analgesia (Numbing the skin)
Origin Synthetic

What Type of Medicine is Anesderm?

Anesderm is defined as a Topical Local Anesthetic and is a combination medicine designed for direct application to the skin surface to induce dermal analgesia. This preparation belongs to the pharmacological class of Amide-type local anesthetic agents because its active ingredients are established synthetic amide compounds. The combination of Lidocaine and Prilocaine is used for its effectiveness in achieving localized topical anesthesia. This product is distinct because its core function is restricted to providing relief that is strictly localized to the skin, contrasting with medications that offer systemic relief. The mixture provides localized anesthesia, and its targeted action minimizes systemic effects.

Composition and Form: The Eutectic Mixture

The two core active ingredients in the preparation are Lidocaine Hydrochloride and Prilocaine, which are synthetic compounds from the amide group. Anesderm is formulated as a topical cream, which is an oil-in-water emulsion system engineered to create a Eutectic Mixture of Local Anesthetics (EMLA). This specialized eutectic state, where the two crystalline agents combine to form a liquid oil, is crucial as it significantly enhances the ingredients' ability to penetrate the intact dermal barrier for effective surface anesthesia. This unique formulation delivers the necessary concentration of both ingredients to the deeper layers of the skin, a feature that allows the combination to achieve a greater depth of anesthesia than would be possible with either ingredient applied alone.

How Anesderm Achieves Dermal Analgesia

The general purpose of Anesderm is to achieve reliable, temporary loss of feeling or numbing of the skin surface, a state pharmacologically termed dermal analgesia. This effect is accomplished when the active ingredients stabilize the membranes of local nerve cells upon topical use, which temporarily inhibits the electrical signaling required for the nerves to transmit feeling. This mechanism is primarily employed to ensure that the skin can be reliably numbed before procedures, mitigating anticipated discomfort or pain, such as the initial sensation associated with injections or minor dermatological interventions.

Regulatory References

  1. Amide-type local anesthetic agents (NIH - National Library of Medicine)

What side effects are possible with Anesderm?

Possible side effects and safety information

The safety profile for Anesderm, a combination of Lidocaine and Prilocaine, is primarily defined by local skin reactions that are generally expected and transient. Regulatory documents categorize these effects based on frequency and the physiological system involved.

Frequency-Classified Adverse Reactions

The majority of documented reactions occur at the application site and resolve following removal of the cream:

  • Very Common (Affecting geq1 in 10 patients): Blanching (pallor), Erythema (redness), and Edema (swelling) at the site of application.
  • Common (Affecting geq1 in 100 to <1 in 10 patients): A sensation of warmth, burning, or itching (pruritus).
  • Uncommon (Affecting geq1 in 1,000 to <1 in 100 patients): Paresthesia (a tingling sensation) or irritation at the application site.

Serious Adverse Reactions and Safety Constraints

While rare, the official safety documentation lists risks of serious systemic reactions that can occur due to excessive absorption or use in susceptible individuals. These include the potential for Methemoglobinemia, a blood disorder, and signs of Systemic Toxicity affecting the Central Nervous System and heart, such as seizures or cardiac arrhythmias, when plasma concentrations are too high. Allergic reactions, including Anaphylaxis, are also listed as rare possibilities.

Specific population-related safety notes exist for infants, particularly those under three months of age, who have an increased vulnerability to Methemoglobinemia. Caution is also noted for patients with severe hepatic or renal impairment as the body's ability to clear the active ingredients may be reduced, potentially increasing systemic exposure. Furthermore, the official label specifies constraints, such as the need for care when applying near the eyes or avoiding application to a compromised eardrum.

Overdose and Emergency Response

Overdose and when to seek help

Systemic toxicity from Anesderm is possible due to excessive systemic absorption, typically when the cream is applied over large surface areas, for prolonged periods, or to compromised skin. The official regulatory profile classifies the risk into two primary systemic domains: Cardioneurotoxicity and Methemoglobinemia.

Overdose Manifestations Required Emergency Actions
Central Nervous System (CNS) Effects: Dizziness, confusion, ringing in the ears (tinnitus), loss of consciousness, or progression to seizure (convulsions).
Metabolic: Signs of methemoglobinemia, including the appearance of cyanosis (bluish or purplish skin/lips) and shortness of breath.
Cardiovascular: Slow heart rate (bradycardia), low blood pressure (hypotension), and irregular heart rhythms. Seek immediate medical attention for any sign of systemic toxicity or methemoglobinemia. Contact emergency services for severe or life-threatening symptoms. The specific antidote for clinically significant methemoglobinemia is Methylthioninium chloride (Methylene Blue). Treatment involves symptomatic and supportive care.

Infants under three months of age and patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency are documented in prescribing information as having an increased risk for methemoglobinemia and seizures. Patients with symptoms of toxicity must be under observation for several hours due to the potential for delayed systemic effects. The official information requires urgent medical evaluation for any manifestation of systemic toxicity.

Therapeutic Uses of Anesderm

What Anesderm Treats: Main Uses and Benefits

The core therapeutic function of Anesderm is to support dermal analgesia (numbing the skin) to ease symptoms related to physical discomfort during necessary interventions. The cream is designed for use on intact skin and on genital mucous membranes across various clinical contexts.

Relief from Acute Procedural Pain

This domain covers the primary use of the cream to support dermal analgesia and help reduce the sharp, localized sensation associated with necessary medical procedures. It is used for managing the acute discomfort and anticipated pain from needle insertions—including those for venipuncture, IV cannulation, and routine vaccinations—which may help patients cope more steadily with these experiences for both adults and pediatric patients.

Support for Minor Dermal Interventions

The medication is applied when appropriate to assist with comfortable execution of minor surgical and dermatological procedures by easing discomfort on the skin surface. This contributes to easing the overall symptom load for interventions like wart removal, curettage, split-skin graft harvesting, or minor genital skin procedures. The cream is also commonly used for managing the acute, procedural pain involved in the mechanical cleansing and debridement of leg ulcers.


Quick Fact: Relief for Procedural Pain

Therapeutic Focus Symptom Category Patient Benefit
Pre-procedural Analgesia Acute, Localized Discomfort Supports patient tolerance and comfort during interventions.
Minor Dermal Interventions Sharp Tactile Sensations Supports a more manageable experience of minor surgeries and biopsies.
Chronic Wound Care Procedural Pain during Debridement Supports patient comfort and coping during symptomatic phases of wound care.

Eligibility and Restrictions for Use

The eligibility for Anesderm is strictly defined by regulatory documents, distinguishing between groups for whom use is permitted, restricted, or contraindicated. Absolute contraindications prohibit use in patients with a known hypersensitivity to amide-type local anesthetics or any of the product’s components. The cream is also strictly contraindicated for patients with congenital or idiopathic methemoglobinemia. Pediatric eligibility is highly restricted: the medicine must not be used on preterm infants (gestational age less than 37 weeks), nor in infants under 12 months who are concurrently receiving methemoglobin-inducing medications. Furthermore, for infants 0–3 months, use is limited to a single application per 24 hours. Conditional use and restrictions apply to several populations. Caution is required for patients with G6PD deficiency or severe hepatic or renal impairment. Application site rules prohibit use on open wounds, cuts, or grazes, with the exception of leg ulcers undergoing debridement. The use of the cream is permitted for lactating mothers, but use during pregnancy is advised as cautious. Safety and efficacy for genital application are not established for children under 12 years.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Anesderm

Interaction Scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions Methemoglobin-inducing agents (e.g., sulfonamides, antimalarials), Local Anesthetic Agents, Class I Antiarrhythmic Drugs, Class III Antiarrhythmic Drugs, and CYP-inhibiting agents (e.g., H2 blockers, beta-blockers).
Specific interacting medicines (if explicitly listed) Cimetidine, Beta-blockers (non-selective), Dapsone, Phenytoin, Phenobarbital, Sulfasalazine, Metoclopramide, Tocainide, Mexiletine, Amiodarone, Dofetilide.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic Interaction (additive risk for methemoglobin formation and systemic toxicity); Pharmacokinetic Interaction (reduced hepatic clearance of lidocaine, leading to increased exposure).
Timing-based interaction rules (if applicable) No mandatory time-separation rules (e.g., "must be separated by X hours") are explicitly listed in regulatory documents for the topical product.
Population-specific interaction notes (if applicable) Infants (0–12 months) have a formally documented contraindication for co-administration with methemoglobin-inducing drugs. Patients with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency are noted to have increased susceptibility to methemoglobinemia from oxidizing agents.
Interaction-related restrictions Contraindication for co-administration with methemoglobin-inducing agents in the specific population of infants 0–12 months. Additive systemic effects risk with other local anesthetics and antiarrhythmics.

Interaction Classifications (High-level)

Category Official Regulatory Classification
Interaction severity classification (as defined in official documents) Contraindicated Combination (for infants 0–12 months); Use with Caution / Monitoring Recommended (for antiarrhythmics and methemoglobin-inducing agents in other populations); Not Clinically Significant for Short-Term Use (for clearance inhibitors).
Regulatory basis (EMA / FDA / etc.) The interaction profile is established and documented in FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC).
Interaction-context constraints (as defined in official documents) Interactions causing reduced clearance are constrained to scenarios involving repeated high doses or prolonged application.

Resulting Interaction Structure

Official regulatory documents detail the additive pharmacodynamic risk with methemoglobin-inducing agents and the additive risk of systemic toxic effects with other local anesthetics and Class I Antiarrhythmic Drugs. This profile includes a formal contraindication for co-administration with methemoglobin-inducing drugs in infants aged 0 to 12 months. Furthermore, the label documents that agents like Cimetidine and Beta-blockers may cause a pharmacokinetic increase in lidocaine exposure by reducing its hepatic clearance. No established interactions with food, alcohol, or herbal products are officially documented. The overall structure classifies known risks and defines limitations strictly based on official regulatory evidence.

Mechanism of Action

Blocking the Pain Signal at the Source (VGSC Inhibition)

Anesderm's primary mechanism involves the reversible blockade of Voltage-Gated Sodium Channels ( VGSCs) located on peripheral sensory nerve fibers. The active ingredients, lidocaine and prilocaine, function as non-selective inhibitors. They diffuse across the neuronal cell membrane to bind to a site within the intracellular portion of the VGSC, stabilizing the channel in its inactivated state. This molecular interaction physically prevents the influx of sodium ions ( Na^+), which is necessary for the initial membrane depolarization.

Interruption of the Peripheral Signaling Pathway

The prevention of Na^+ influx halts the generation and propagation of the action potential (the electrical impulse). This action interrupts the mechanistic cascade of signal transmission within the peripheral somatosensory pathway. The mechanism is localized to the afferent sensory nerves, resulting in a localized alteration in impulse conduction.

Mechanism of Action via Synergistic Amide Anesthetics

The combination of lidocaine and prilocaine optimizes the drug's kinetics, improving the efficiency of skin penetration and regulating the duration of the VGSC block. This synergistic activity supports a robust, prolonged physiological period of local anesthesia by maintaining the cessation of sensory input at the site of application.

Dosage and Administration Information

How to Use Anesderm

Anesderm is used strictly as a topical cream for application to intact skin, genital mucosa, and leg ulcers, under specific parameters for dosing and timing. The application method allows the two active ingredients, lidocaine and prilocaine, to reach the necessary concentration in the skin.


Administration Scope and Dosing

Usage Condition Dosing and Application Time
Minor Dermal Procedures (Intact Skin) Apply 2.5 g over 20 to 25 cm^2 for a minimum of 1 hour.
Major Dermal Procedures Apply approximately 1.5 g to 2 g per 10 cm^2 for at least 2 hours.
Adult Genital Mucosa Application is typically 5 to 10 g for 5 to 10 minutes prior to minor superficial procedures.
Leg Ulcer Debridement Apply 1 g to 2 g per 10 cm^2 (max 10 g total) for 30 to 60 minutes.

The maximum recommended total adult dose for large-area dermal procedures is 60 g over a 600 cm^2 maximum area. The maximum application time for general intact skin use is 5 hours, after which effectiveness may decrease.


Procedural and Population Rules

For most procedures, the cream is applied as a thick, non-rubbed-in layer and must be covered with an occlusive dressing to promote absorption. The procedure typically commences after the cream and dressing are removed. Dosing for pediatric patients is based on age and body surface area, with infants 0 to 2 months having a maximum 1 hour application time and a single-dose limit per 24 hour period. Patients with atopic dermatitis have a reduced application time of 15 to 30 minutes.

Recent Clinical Evidence

Research evidence / Overview of studies for Anesderm


Research Structure and Core Evidence

The clinical evaluation of Anesderm was studied for its role in dermal analgesia, the outcomes related to physical discomfort that research explored. The research base is supported by Randomized Controlled Trials (RCTs) and Systematic Reviews (meta-analyses), which are key study types used in research exploring how symptoms change over time. Research in this field has explored its application in research scenarios where symptoms become more noticeable due to necessary medical procedures. The studies contribute to the broader evidence landscape when the cream was studied for pre-treatment use.


Evidence for Dermal Analgesia During Acute Procedures

The primary research for the cream was studied for its role in settings involving acute procedures, such as venipuncture (drawing blood) and IV cannulation (inserting a catheter). In these trials, researchers examined various outcomes monitoring physiological responses, including measures of patient-reported outcomes describing perceived discomfort and involuntary physiological responses (e.g., heart rate changes and duration of crying in infants).

In controlled trials, the application of the cream for the time interval studied data show patterns related to measured outcomes examined in research exploring how symptoms change over time, when compared to a placebo cream. These findings describe group patterns, not personal outcomes, and study results reflect the specific conditions under which they were conducted.


Evidence for Support During Minor Dermatological Interventions

The combination cream was evaluated in studies focusing on its application in research scenarios involving minor surgical and dermatological procedures. This research explored short-term symptom changes associated with procedures like split-skin graft harvesting and the debridement of leg ulcers. The study outcomes examined included patient-reported outcomes describing perceived discomfort during the procedure itself, and objective measures to assess the depth of numbness achieved on the skin.

Research describes that the onset and intensity of numbness was observed in some studies to vary depending on the area of the body where the cream was applied, such as genital skin compared to thicker intact skin. The evidence contributes to understanding symptom patterns but research does not determine whether an individual will respond similarly.


Research Gaps and Areas of Uncertainty

Research has explored the cream’s use in various patient groups, including adults and pediatric patients. However, evidence is limited for its use in neonates (infants up to one month old) in procedures where comparative data are insufficient. Further, the research structure has not characterized the cream’s use as the sole anesthetic agent for surgical procedures that require deep, full-thickness anesthesia. Follow-up durations were limited to the acute procedural period.

Frequently Asked Questions (FAQ)

Common questions about Anesderm (FAQ)


Q: How does Anesderm differ from a standard over-the-counter pain reliever cream?

Anesderm is classified by regulators as a topical local anesthetic, meaning it works by temporarily blocking the electrical signals sent by nerves in the area where it is applied, creating a localized numbing effect known as dermal analgesia. This is different from many standard over-the-counter pain relief creams, which often rely on reducing inflammation or affecting pain signals in a different way. The official product information notes that Anesderm's core function is restricted to providing strictly localized relief.


Q: How quickly does Anesderm usually start to work after application?

According to the official application guidelines, the numbing effect begins after a necessary minimum application time. For most applications on intact skin, the required application period is usually one hour or more to allow for sufficient absorption. For applications on genital mucosa, the required time frame is shorter. The official guidelines define the minimum application time needed before a procedure can commence.


Q: What is the typical duration of the numbing effect from Anesderm?

The numbing effect is designed to be temporary, lasting only as long as required for the procedure. Official information indicates that the local anesthetic effect typically persists for approximately one to two hours after the cream and the required occlusive dressing have been removed from the skin.


Q: Why does the onset of effect seem to vary among users?

Official documents and research indicate that the time needed for the numbing effect to set in and its intensity may vary due to several factors. These factors include the application site on the body, such as thicker intact skin compared to genital skin. Patients with certain skin conditions, such as atopic dermatitis, are officially noted to require a reduced application time.


Q: What are the official warnings regarding the use of Anesderm with other topical medications?

Regulatory documents include a specific warning about the risk of additive systemic effects when Anesderm is used with other local anesthetic agents. The official documents do not explicitly list warnings for non-anesthetic topical medicines. The required application protocol (thick layer, occlusive dressing) is designed to ensure proper absorption and must be followed for effective drug delivery.


Q: Are there different strengths or formulations of Anesderm available?

The official product information defines Anesderm as a single-formulation Topical Cream that is an oil-in-water emulsion. This cream is a specialized eutectic mixture of Lidocaine and Prilocaine. Other strengths or different topical formulations (such as patches or gels) under the Anesderm brand name are not described in the official prescribing information.


Q: Can Anesderm be used multiple times in one day, based on general guidelines?

For infants aged 0 to 3 months, regulatory rules impose a strict limit of a single application per 24 hours. For adults and older children, official guidelines define maximum limits for the dose and area for each application, but they do not provide a general maximum frequency of use per 24 hours.


Q: Is Anesderm considered a controlled substance?

Based on regulatory scheduling and official guidance, the active ingredients in the Anesderm topical formulation are not generally classified as controlled substances by major governmental drug enforcement agencies. The product is governed by standard prescription drug regulations, not those for controlled substances.


Q: Are there any known long-term or delayed side effects from Anesderm use?

Research evidence supporting Anesderm's approval was focused primarily on the acute procedural period. Official regulatory information discusses risks associated with immediate or near-immediate use, such as the potential for Methemoglobinemia or Systemic Toxicity. However, information regarding long-term or chronic side effects following repeated use is not characterized in the current research structure.


Q: Can Anesderm be used at the same time as common skin care products or moisturizers?

Official regulatory information does not document established interactions with non-medicinal products like food, alcohol, or herbal supplements. The required application protocol involves applying the cream as a thick layer covered by an occlusive dressing to promote absorption. Applying other products simultaneously is not addressed in regulatory warnings, but the protocol emphasizes maintaining the thick layer and occlusive covering to ensure proper drug delivery.


Q: Are there any documented restrictions for older adults (geriatric patients) using Anesderm?

Regulatory documents do not list an absolute contraindication for use based only on advanced age. However, regulatory documents specify that the potential for reduced clearance should be considered for older adults who have existing issues with their liver, kidney, or heart function. These conditions can potentially increase the risk of systemic exposure.


Q: What is the purpose of the inactive ingredients in the Anesderm formulation?

The inactive ingredients are essential for the cream's stability and specialized delivery system. Their primary purpose is to help create the Eutectic Mixture, which is an oil-in-water emulsion. This unique mixture is necessary to enable the active ingredients to effectively penetrate the skin's surface and achieve dermal anesthesia.


Q: Is Anesderm typically available only by prescription?

According to regulatory documentation, Anesderm is designated as a Human Prescription Drug in the United States. This designation means that access and use are generally controlled by a valid prescription and guided by the detailed Prescribing Information supplied by the official regulatory body.


Q: What should be avoided immediately after the effect of Anesderm wears off?

The official label contains warnings regarding the loss of protective reflexes when the skin is numb, which could hide injuries. The safety constraints specify that the treated area should not be rubbed or scratched, and contact with very hot or very cold objects should be avoided until normal sensation has fully returned.


Q: What is the difference between Anesderm and a generic version of a similar topical anesthetic?

Regulatory standards dictate that a generic version of a drug must contain the same active ingredients and be the same strength as the brand-name product, ensuring the same clinical benefit. Any differences are generally confined to non-therapeutic characteristics, such as the color, packaging, or the non-active components (inactive ingredients) used in the cream's formulation.


Q: What are the risks described in regulatory sources regarding accidental ingestion of Anesderm?

The official label contains a safety warning regarding exposure of the cream to the mouth. The documentation specifies that serious unwanted effects may occur if the medicine is swallowed. Accidental ingestion can lead to substantial absorption into the bloodstream, posing a risk of systemic toxicity that can affect the body, including the brain and heart.


Q: Does Anesderm have a potential for abuse or dependence?

The active ingredients in Anesderm are topical local anesthetics, which is a class of drug generally not associated with misuse or dependence. Official regulatory documents do not typically cite a potential for abuse or dependence for this specific topical formulation.

How should Anesderm be stored and disposed of?

How to Store and Dispose of ANESDERM (Lidocaine/Prilocaine Cream)

The storage and disposal of ANESDERM are governed by regulatory requirements to maintain the cream's efficacy and ensure safety.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (not above 30 C).
Prohibition Do not freeze the cream, as this can compromise its formulation.
Safety The product must be kept strictly out of the sight and reach of children.
Handling Keep the container tightly closed to protect the cream's integrity.

Disposal Instructions

Unused or expired ANESDERM must not be disposed of in household trash or via wastewater, as officially stated. Any medicine no longer needed must be discarded according to local pharmaceutical waste management guidelines, usually by consulting a pharmacist for safe take-back options. Furthermore, any cream remaining in a tube used for leg ulcer treatment must be discarded after the single application.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anesderm found in:

A-Z Index: